Premium
Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab
Author(s) -
Kobayashi Tetsuo,
Yokoyama Tomoko,
Ito Satoshi,
Kobayashi Daisuke,
Yamagata Akira,
Okada Moe,
Oofusa Ken,
Narita Ichiei,
Murasawa Akira,
Nakazono Kiyoshi,
Yoshie Hiromasa
Publication year - 2014
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2014.140194
Subject(s) - medicine , adalimumab , rheumatoid arthritis , gastroenterology , etanercept , bleeding on probing , tumor necrosis factor alpha , serum amyloid a , saliva , periodontitis , immunology , inflammation
Background: Tumor necrosis factor (TNF)‐α inhibitor has been shown to affect the periodontal condition of patients with rheumatoid arthritis (RA). The aim of the present study is to assess the effect of a fully humanized anti‐TNF‐α monoclonal antibody, adalimumab (ADA), on the periodontal condition of patients with RA and to compare serum protein profiles before and after ADA therapy. Methods: The study participants consisted of 20 patients with RA treated with ADA. Clinical periodontal and rheumatologic parameters and serum cytokine levels were evaluated at baseline and 3 months later. Serum protein spot volume was examined with two‐dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins with significant difference in abundance before and after ADA therapy were found and identified using mass spectrometry and protein databases. Results: The patients showed a significant decrease in gingival index ( P = 0.002), bleeding on probing ( P = 0.003), probing depth ( P = 0.002), disease activity score including 28 joints using C‐reactive protein ( P <0.001), and serum levels of TNF‐α ( P <0.001) and interleukin‐6 ( P <0.001) after ADA medication, although plaque levels were comparable. Among a total of 495 protein spots obtained, nine spots were significantly decreased in abundance at reassessment, corresponding to complement factor H, phospholipase D, serum amyloid A, complement component 4, and α‐1‐acid glycoprotein ( P <0.01). Conclusion: These results suggest a beneficial effect of ADA therapy on the periodontal condition of patients with RA, which might be related to differences in serum protein profiles before and after ADA therapy.